Overview

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Status:
Completed

Trial end date:
2019-08-13

Target enrollment:

Participant gender:

Summary

"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)-inhibitor induced anticoagulation; and 2) evaluate the safety and PK/PD of andexanet in healthy Japanese subjects taking direct FXa inhibitors at therapeutic doses."

Phase:

Phase 2

Details

Lead Sponsor:

Portola Pharmaceuticals

Treatments:

Apixaban
Edoxaban
Factor Xa Inhibitors
Rivaroxaban